The relevance of high-dose chemotherapy followed by auto-SCT in CLL remains to be defined. The aim of the prospective, randomized, GOELAMS LLC 98 trial was to compare two strategies in previously untreated CLL patients aged 60 years. Conventional chemotherapy (Arm A) consisted of six monthly courses of CHOP followed by six CHOP courses in every 3 months in those achieving a complete or PR. Arm A was compared with high-dose therapy with auto-SCT (Arm B), used as consolidation after three CHOP courses in case of CR or very good PR. A total of 86 patients were enrolled, of which 39 and 43 patients were evaluable in arm A and arm B, respectively. The primary endpoint was PFS. On an intent-to-treat basis and with a median follow-up time of 77.1 (range 1-135.5) months, the median PFS was 22 months in Arm A and 53 months in Arm B (P<0.0001). Median survival time was 104.7 months in arm A and 107.4 months in arm B. This trial demonstrates that frontline high-dose therapy with auto-SCT prolongs PFS but does not translate into a survival advantage in advanced CLL patients in the pre-rituximab era. © 2012 Macmillan Publishers Limited. All rights reserved.
CITATION STYLE
Brion, A., Mahé, B., Kolb, B., Audhuy, B., Colombat, P., Maisonneuve, H., … Feugier, P. (2012). Autologous transplantation in CLL patients with B and C Binet stages: Final results of the prospective randomized GOELAMS LLC 98 trial. Bone Marrow Transplantation, 47(4), 542–548. https://doi.org/10.1038/bmt.2011.117
Mendeley helps you to discover research relevant for your work.